Does the media refer more to CRVS or AKBA?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 0.89 beat Akebia Therapeutics' score of 0.70 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GLUE or AKBA?

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Monte Rosa Therapeutics and 2 mentions for Akebia Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Akebia Therapeutics' score of 0.70 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABUS or AKBA?

In the previous week, Arbutus Biopharma had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for Arbutus Biopharma and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat Arbutus Biopharma's score of 0.16 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AKBA or SANA?

In the previous week, Sana Biotechnology had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat Sana Biotechnology's score of 0.46 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AKBA or AVBP?

In the previous week, ArriVent BioPharma had 18 more articles in the media than Akebia Therapeutics. MarketBeat recorded 20 mentions for ArriVent BioPharma and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat ArriVent BioPharma's score of 0.14 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Akebia Therapeutics (AKBA) Competitors

$0.70 -0.01 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 +0.00 (+0.07%)

As of 05:42 PM Eastern

Compare

AKBA vs. CRVS, GLUE, ABUS, SANA, and AVBP

Should you buy Akebia Therapeutics stock or one of its competitors? Akebia Therapeutics's main competitors and comparable companies include Corvus Pharmaceuticals (CRVS), Monte Rosa Therapeutics (GLUE), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), and ArriVent BioPharma (AVBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Corvus Pharmaceuticals' return on equity of -36.15% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 255.37%. Akebia Therapeutics has a consensus price target of $3.90, indicating a potential upside of 455.56%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corvus Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 0.89 beat Akebia Therapeutics' score of 0.70 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Akebia Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Akebia Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Akebia Therapeutics has a net margin of -13.54% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Monte Rosa Therapeutics presently has a consensus price target of $26.67, indicating a potential upside of 171.00%. Akebia Therapeutics has a consensus price target of $3.90, indicating a potential upside of 455.56%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Monte Rosa Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	6.79	-$38.63M	-$1.76	N/A
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Monte Rosa Therapeutics and 2 mentions for Akebia Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.98 beat Akebia Therapeutics' score of 0.70 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monte Rosa Therapeutics beats Akebia Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Akebia Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Arbutus Biopharma has a net margin of 84.22% compared to Akebia Therapeutics' net margin of -13.54%. Arbutus Biopharma's return on equity of 90.98% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Arbutus Biopharma has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 19.33%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 455.56%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Arbutus Biopharma. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$181.72M	4.57	-$33.50M	$0.79	5.30
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A

In the previous week, Arbutus Biopharma had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for Arbutus Biopharma and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat Arbutus Biopharma's score of 0.16 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats Akebia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Sana Biotechnology?

Akebia Therapeutics (NASDAQ:AKBA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Akebia Therapeutics has higher revenue and earnings than Sana Biotechnology. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sana Biotechnology had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat Sana Biotechnology's score of 0.46 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sana Biotechnology has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Sana Biotechnology	N/A	-103.02%	-39.16%

Akebia Therapeutics currently has a consensus price target of $3.90, indicating a potential upside of 455.56%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 300.57%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Akebia Therapeutics has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Summary

Sana Biotechnology beats Akebia Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to ArriVent BioPharma?

Akebia Therapeutics (NASDAQ:AKBA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

ArriVent BioPharma has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. ArriVent BioPharma's return on equity of -50.26% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Akebia Therapeutics has higher revenue and earnings than ArriVent BioPharma. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

In the previous week, ArriVent BioPharma had 18 more articles in the media than Akebia Therapeutics. MarketBeat recorded 20 mentions for ArriVent BioPharma and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.70 beat ArriVent BioPharma's score of 0.14 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics presently has a consensus target price of $3.90, indicating a potential upside of 455.56%. ArriVent BioPharma has a consensus target price of $27.44, indicating a potential upside of 69.41%. Given Akebia Therapeutics' higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Akebia Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Summary

ArriVent BioPharma beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$192.73M	$3.96B	$7.43B	$12.93B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-6.32	12.51	274.95	25.40
Price / Sales	0.82	1,136.11	568.69	75.42
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	5.80	15.79	10.32	6.02
Net Income	-$5.34M	-$22.69M	$3.49B	$380.68M
7 Day Performance	-14.64%	-4.31%	-2.55%	-3.01%
1 Month Performance	-22.98%	-11.49%	-6.88%	-5.59%
1 Year Performance	-76.42%	4.54%	1.80%	-5.24%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.5826 of 5 stars	$0.70 -0.9%	$3.90 +460.7%	-74.8%	$192.73M	$236.20M	N/A	194	Positive News
CRVS Corvus Pharmaceuticals	2.0456 of 5 stars	$10.05 -4.5%	$33.33 +231.7%	+33.2%	$884.95M	N/A	N/A	37	Positive News
GLUE Monte Rosa Therapeutics	2.6264 of 5 stars	$10.52 +2.1%	$26.67 +153.5%	-7.3%	$878.72M	$28.73M	N/A	173	Positive News
ABUS Arbutus Biopharma	2.0347 of 5 stars	$4.15 -1.7%	$5.00 +20.5%	-1.2%	$836.01M	$14.08M	5.25	19	Short Interest Increase
SANA Sana Biotechnology	3.4191 of 5 stars	$2.62 -6.1%	$9.33 +256.2%	-47.6%	$835.22M	N/A	N/A	142

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. CRVS, GLUE, ABUS, SANA, and AVBP

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Akebia Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Akebia Therapeutics compare to Arbutus Biopharma?

Summary

How does Akebia Therapeutics compare to Sana Biotechnology?

Summary

How does Akebia Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. CRVS, GLUE, ABUS, SANA, and AVBP

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Is CRVS or AKBA more profitable?

Do analysts prefer CRVS or AKBA?

Which has more volatility and risk, CRVS or AKBA?

Which has stronger valuation and earnings, CRVS or AKBA?

Does the media refer more to CRVS or AKBA?

Do insiders & institutionals hold more shares of CRVS or AKBA?

Summary

How does Akebia Therapeutics compare to Monte Rosa Therapeutics?

Is GLUE or AKBA more profitable?

Do analysts prefer GLUE or AKBA?

Do insiders and institutionals believe in GLUE or AKBA?

Which has more volatility & risk, GLUE or AKBA?

Which has better earnings and valuation, GLUE or AKBA?

Does the media refer more to GLUE or AKBA?

Summary

How does Akebia Therapeutics compare to Arbutus Biopharma?

Is ABUS or AKBA more profitable?

Which has more risk & volatility, ABUS or AKBA?

Do analysts rate ABUS or AKBA?

Do insiders & institutionals have more ownership in ABUS or AKBA?

Which has stronger valuation & earnings, ABUS or AKBA?

Does the media prefer ABUS or AKBA?

Summary

How does Akebia Therapeutics compare to Sana Biotechnology?

Which has higher earnings and valuation, AKBA or SANA?

Do institutionals & insiders believe in AKBA or SANA?

Does the media refer more to AKBA or SANA?

Is AKBA or SANA more profitable?

Do analysts prefer AKBA or SANA?

Which has more risk & volatility, AKBA or SANA?

Summary

How does Akebia Therapeutics compare to ArriVent BioPharma?

Is AKBA or AVBP more profitable?

Which has better earnings and valuation, AKBA or AVBP?

Does the media favor AKBA or AVBP?

Do analysts rate AKBA or AVBP?

Do institutionals and insiders believe in AKBA or AVBP?

Which has more volatility & risk, AKBA or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools